Pathkey.AI Names Defence and Enterprise Tech Veteran as CEO to Drive Dual AI Platform Push

Pathkey.AI Ltd (ASX: PKY) has appointed Andrew Farnsworth as Chief Executive Officer, effective 11 May 2026. Farnsworth transitions into the role following a six-month consulting engagement with the Company, during which he contributed to strategic direction across both the TrialKey clinical trials platform and the recently announced Chipforge AI-powered chip design platform for semiconductor engineering.

The appointment reflects Pathkey’s broadening ambition as an applied AI company with a commercial footprint extending beyond healthcare. Farnsworth will lead the commercialisation of both platforms as the Company advances its pending acquisition of Singapore-based Chipforge.

Chair Shannon Robinson

“Andrew’s appointment comes at a pivotal point in Pathkey’s development with the planned acquisition of Singapore-based Chipforge. His background combines defence communications, secure systems, infrastructure, product architecture, enterprise-scale delivery, and commercialisation. That combination aligns strongly with Pathkey’s strategy of developing and commercialising AI-based large language model platforms applied to data-intensive industries, with TrialKey serving clinical research and Chipforge positioned to serve customers across sectors including healthcare, defence, critical infrastructure and other regulated industries.”

From the RAAF to billion-dollar tech platforms — who is Andrew Farnsworth?

Farnsworth’s career began in the Royal Australian Air Force, where he developed expertise in high-security radio, encrypted communications, and mission-critical IT operations, including work involving cryptographic equipment and protected networks. That foundation shaped a professional trajectory spanning defence-aligned environments, global enterprise technology, and founder-led product development.

His career highlights include:

1. Yum! Brands (NYSE: YUM, US$43B market cap): Directed technology strategy and product development across ecommerce, payments, AI/Machine Learning, restaurant systems, architecture, and data platforms, helping grow digital revenue to approximately USD 1.5 billion.

2. Sephora Asia: Led regional enterprise technology encompassing store systems, payment platforms, ERP, data and analytics, and fulfilment operations.

3. Marina Bay Sands: Oversaw major portfolios spanning cybersecurity, infrastructure, enterprise architecture, surveillance systems, and large-scale data centre modernisation.

4. Founder experience: Built and commercialised a secure mobile payments and customer engagement platform end-to-end, securing funding, validating a revenue model, and scaling early market traction.

Across more than 20 years, Farnsworth has operated at the intersection of secure systems, AI-enabled platforms, and large-scale commercial execution, a profile that directly maps to the dual-platform mandate Pathkey is now pursuing.

Why this appointment matters for Pathkey’s AI strategy

TrialKey and Chipforge — two platforms, one commercial mandate

Farnsworth’s consulting engagement was not incidental. He played a direct role in advising the Board’s decision to pursue the Chipforge acquisition, connecting his six months of strategic input to one of the Company’s most material near-term transactions.

Pathkey’s dual-platform strategy centres on two distinct but architecturally related products. TrialKey targets clinical trial design and optimisation, while Chipforge (Singapore-based, acquisition pending) is an AI-powered chip design platform aimed at sectors including healthcare, defence, critical infrastructure, and other regulated industries. The shared foundation is an agent-based AI architecture combining large language model functionality with neuro-symbolic reasoning.

For investors less familiar with the technical framing, agent-based AI architecture means AI agents generate candidate solutions, evaluate them against defined objectives, and iteratively refine outputs through a structured reflection loop. This approach underpins the defensibility and differentiation of both platforms by making outputs more verifiable and domain-specific than general-purpose AI tools.

CEO Andrew Farnsworth

“Pathkey is harnessing the power of AI and large language models to build solutions for industries where reliability and precision truly matter. AI represents one of the most significant technological revolutions in human history, and I’m energised by the opportunity to work with the Board and the team to accelerate the Company’s AI strategy. That includes strengthening our technology and IP base, and unlocking the natural synergies between the two exciting platforms — TrialKey and Chipforge — with a clear focus on near‑term commercialisation”

Compensation structure signals performance alignment

Farnsworth’s remuneration package is structured to align his incentives with shareholder outcomes across both near-term revenue milestones and longer-dated platform delivery triggers.

Two LTI conditions are particularly relevant to investors tracking Pathkey’s progress. The $0.06 VWAP hurdle (Tranche 2) ties a material portion of Farnsworth’s equity upside directly to share price performance over a sustained 15-day window. The TrialKey commercialisation trigger (Tranche 4) requires execution of a binding strategic partnership or customer agreement that genuinely embeds the platform in a partner’s operational workflow, not merely a letter of intent. Together, these conditions tie the long-term incentive structure to outcomes that are observable and meaningful for shareholders.

Don’t Miss the Next ASX Tech Appointment That Could Move Markets

Big News Blast delivers FREE breaking ASX tech and AI news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market. Click the “Free Alerts” button at StockWire X to never miss a market-moving announcement again.